Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
- 28 April 2012
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 27 (1), 11-18
- https://doi.org/10.1111/j.1468-3083.2012.04546.x
Abstract
Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway have been detected in a variety of tumor entities, including malignant melanoma, thyroid, colonic and ovarian carcinomas, and some sarcomas. Thus, a number of inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Up to now one drug of this category (vemurafenib) has been approved by the FDA and the European Commission for late-stage melanoma. Although these new targeted anticancer therapies are generally considered to be safe and well tolerated, certain toxicities have been attributed to them, with cutaneous side effects being perhaps the most frequent amongst them. Based on results of clinical trials and on case series, a distinct profile of cutaneous toxicity has been observed, which is similar to that of EGFR and multikinase inhibitors. As exanthema, palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, xerosis, pruritus, photosensitivity, and paronychia, can be controlled in most cases with common conservative modalities, special attention should be given to the early detection of epithelial skin tumors (mainly keratoakanthomas) that can be induced during therapy with these agents. This report reviews all current published data on cutaneous side effects of RAS-RAF-MEK-ERK pathway inhibitors, and attempts to provide the clinician with clear hints for their management.Keywords
This publication has 56 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Targeting BRAF for patients with melanomaBritish Journal of Cancer, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Opposing roles for calcineurin and ATF3 in squamous skin cancerNature, 2010
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersJournal of Clinical Oncology, 2008
- Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- A Role for the Mitogen-activated Protein Kinase Kinase Kinase 1 in Epithelial Wound HealingMolecular Biology of the Cell, 2006
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Mutations of the BRAF gene in human cancerNature, 2002